ReviewEuropean journal of medical research2022
The focus clinical research in intrahepatic cholangiocarcinoma.
Review in European journal of medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Development and Validation of a Machine-Learning Model to Predict Early Recurrence of Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2023Trial
- Rising Intrahepatic Cholangiocarcinoma Rates in the United States Are Driving Liver Cancer Rates in Females.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Article
- The CXCL5/CXCR2 Axis Attenuates Ferroptosis in Intrahepatic Cholangiocarcinoma Through the Positive Feedback Loop Between PTGS2 Transcriptional Activation and Neutrophil Recruitment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Risk of Long-Term Survival After Hepatic Resection for Hepatocellular and Intrahepatic Cholangiocarcinoma: Population-Based Analysis in Korea.Journal of Korean medical science · 2026Article
- A pyroptosis-related molecular signature stratifies prognosis and highlights GSDMB-mediated malignancy in intrahepatic cholangiocarcinoma.Biology direct · 2026Article
- The LINC00519/hsa-miR-22-3p/MECOM Axis Accelerates Intrahepatic Cholangiocarcinoma Progression through PI3K/AKT Signaling.Molecular cancer research : MCR · 2025Article
- The clinical value of lymph-node dissection in hepatitis B virus-associated intrahepatic cholangiocarcinoma.Medicine · 2025Observational
- Who benefits from adjuvant chemotherapy? Identification of early recurrence in intrahepatic cholangiocarcinoma patients after curative-intent resection using machine learning algorithms.Frontiers in oncology · 2025Article
- FGFR2 fusion/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma.The oncologist · 2024Article
- Predictive value of HTS grade in patients with intrahepatic cholangiocarcinoma undergoing radical resection: a multicenter study from China.World journal of surgical oncology · 2024Article
- Research progress and prospect of postoperative adjuvant therapy for resectable intrahepatic cholangiocarcinoma.Frontiers in pharmacology · 2024Review
- Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with serum markers in at-risk patients with hepatitis B virus.Quantitative imaging in medicine and surgery · 2023Article
- Response Assessment of Primary Liver Tumors to Novel Therapies: an Imaging Perspective.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023Review
- Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma.Frontiers in immunology · 2023Article
- Correction to: The focus clinical research in intrahepatic cholangiocarcinoma.European journal of medical research · 2022Article
- Progress in gallbladder cancer with lymph node metastasis.Frontiers in oncology · 2022Review
- Perihilar and Intrahepatic Cholangiocarcinoma after Resection: Clinicopathological Characteristics, Outcomes, and Implications for Addition of Chemoradiotherapy.Euroasian journal of hepato-gastroenterologyArticle
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Intrahepatic cholangiocarcinoma (ICC), highly invasive and highly heterogeneous, has a poor prognosis. It has been confirmed that many risk factors are associated with ICC including intrahepatic lithiasis, primary sclerosing cholangitis (PSC), congenital abnormalities of the bile ducts, parasite infection, toxic exposures chronic liver disease (viral infection and cirrhosis) and metabolic abnormalities. In recent years, significant progress has been made in the clinical diagnosis and treatment of ICC. Advances in functional and molecular imaging techniques offer the possibility for more accurate preoperative assessment and detection of recurrence. Moreover, the combination of molecular typing and traditional clinical pathological typing provides accurate guarantee for clinical decision-making. Surgical resection is still the only radical treatment for ICC, while R0 resection, lymph node dissection, postoperative adjuvant therapy and recurrence resectomy have been confirmed to be beneficial for patients. New therapies including local therapy, molecular targeted therapy and immunotherapy are developing rapidly, which brings hopeful future for advanced ICC. The combination of traditional therapy and new therapy is the future development direction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.